Skip to content

Advertisement

  • Poster presentation
  • Open Access

Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro

  • 1,
  • 1,
  • 1,
  • 2,
  • 3,
  • 3,
  • 3,
  • 2 and
  • 1
Journal for ImmunoTherapy of Cancer20131(Suppl 1):P263

https://doi.org/10.1186/2051-1426-1-S1-P263

Published: 7 November 2013

Keywords

  • Mantle Cell Lymphoma
  • SCID Mouse
  • Raji Cell
  • Mantle Cell Lymphoma Cell
  • Strong Growth Inhibition

Background

We previously reported an anti-CD20-interferon-alpha (IFNα) fusion protein able to induce apoptosis and promote in vivo eradication of a human CD20-expressing mouse B cell lymphoma [Xuan et al, Blood 2010]. We now report the activity of a recombinant anti-CD20-human IFNα fusion protein against human non-Hodgkin B cell lymphomas (NHL).

Methods

Anti-CD20-hIFNα was evaluated against a panel of human Burkitt, diffuse large B cell (DLBCL), and mantle cell lymphoma cell lines. Proliferation was measured by [3H]-thymidine, complement-dependent cytotoxicity (CDC) by PI flow cytometry, and antibody-dependent cellular cytotoxicity (ADCC) by LDH release using PBMC effectors. NHL xenografts were grown in SCID mice.

Results

Anti-CD20-hIFNα induced stronger growth inhibition than rituximab, particularly against Burkitt and germinal center-type DLBCL NHLs. Tumor growth inhibition by anti-CD20-hIFNα was associated with substantial apoptosis in some cell lines. Anti-CD20-hIFNα exhibited potent ADCC activity against Daudi, Ramos, and Raji cells, identical to rituximab. Surprisingly, anti-CD20-hIFNα exhibited superior CDC compared to rituximab against Daudi, Ramos, and Raji cells that was dependent upon linkage of IFNα to the anti-CD20 antibody, and correlated with improved complement fixation. Importantly, against Raji NHL xenograft tumors in SCID mice, anti-CD20-hIFNα achieved superior efficacy compared to rituximab (p=0.0015) and control fusion protein (p<0.0001). At antibody doses at which Raji xenograft tumors progressed through rituximab, anti-CD20-hIFNα eradicated 50-88% of established tumors. Non-targeted control fusion protein had only minor effects on tumor growth.

Conclusions

Anti-CD20-hIFNα has stronger direct anti-proliferative and CDC activities than rituximab against human NHL while retaining potent ADCC activity, and also has the ability to eradicate established NHL xenografts in vivo. These results support the further development of anti-CD20-hIFNα for the treatment of B cell NHL, and a phase I first-in-human clinical trial is currently being planned.

Authors’ Affiliations

(1)
Medicine - Hematology/Oncology, UCLA, Los Angeles, USA
(2)
Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, USA
(3)
ImmunGene, Inc. and Valor Biotherapeutics, Thousand Oaks, USA

Copyright

© Yamada et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement